David Cook - ALLIANCE PHARMA Independent Non-Executive Director

DVL Stock  EUR 0.43  0.01  2.38%   

Director

David Cook is NonExecutive Independent Director of Alliance Pharma Plc. David joined the board of Alliance as a nonexecutive director on 1 April 2014. He is currently Chief Financial Officer and Chief Business Officer of Biotie Therapies Corporationration a drug development company quoted in Helsinki on the NASDAQ OMX market. He has previously held senior financial positions with Jazz Pharmaceuticals International EUSA Pharma Inc and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford. since 2014.
Age 48
Tenure 10 years

Similar Executives

Showing other executives

DIRECTOR Age

Michael GrimmApple Inc
63
David ConstableApple Inc
56
Richard GeorgeApple Inc
65
Sean GourleyApple Inc
38
Mark McKinleyApple Inc
60
Mark McKinleyApple Inc
60
David ConstableApple Inc
56
Alexandra PrunerApple Inc
56
Sean GourleyApple Inc
38
Richard GeorgeApple Inc
65
Peter FluorApple Inc
70
Claire FarleyApple Inc
59
Eric MullinsApple Inc
55
Paulett EberhartApple Inc
64
Joseph GorderApple Inc
60
Paulett EberhartApple Inc
64
Claire FarleyApple Inc
59
Kevin ChiltonApple Inc
60
Anthony ChaseApple Inc
63
Anthony ChaseApple Inc
63
Joseph GorderApple Inc
60
ALLIANCE PHARMA (DVL) is traded on Berlin Exchange in Germany and employs 13 people.

ALLIANCE PHARMA Leadership Team

Elected by the shareholders, the ALLIANCE PHARMA's board of directors comprises two types of representatives: ALLIANCE PHARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ALLIANCE. The board's role is to monitor ALLIANCE PHARMA's management team and ensure that shareholders' interests are well served. ALLIANCE PHARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ALLIANCE PHARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarah Robinson, Company Secretary
David Cook, Independent Non-Executive Director
Janice Timberlake, Director of Human Resources
Andrew Franklin, Finance Director, Director
John Dawson, CEO, Executive Director
Stephen Kidner, Other - Operations Director
Dan Thomas, Other - Business Development Director
Anthony Booley, Executive Director
Andrew Smith, Non-Executive Director
Nigel Clifford, Independent Non-Executive Director
Margaret Boulton, Other - Medical and Regulatory Affairs Director
Thomas Casdagli, Non-Executive Director
Peter Butterfield, Executive Director

ALLIANCE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ALLIANCE PHARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ALLIANCE PHARMA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ALLIANCE PHARMA's short interest history, or implied volatility extrapolated from ALLIANCE PHARMA options trading.

Pair Trading with ALLIANCE PHARMA

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ALLIANCE PHARMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALLIANCE PHARMA will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to ALLIANCE PHARMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ALLIANCE PHARMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ALLIANCE PHARMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ALLIANCE PHARMA to buy it.
The correlation of ALLIANCE PHARMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ALLIANCE PHARMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ALLIANCE PHARMA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ALLIANCE PHARMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ALLIANCE PHARMA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for ALLIANCE Stock analysis

When running ALLIANCE PHARMA's price analysis, check to measure ALLIANCE PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ALLIANCE PHARMA is operating at the current time. Most of ALLIANCE PHARMA's value examination focuses on studying past and present price action to predict the probability of ALLIANCE PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ALLIANCE PHARMA's price. Additionally, you may evaluate how the addition of ALLIANCE PHARMA to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Please note, there is a significant difference between ALLIANCE PHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine if ALLIANCE PHARMA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ALLIANCE PHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.